Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26,585 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Level 2 Clear all
Not listed Phase 3 Interventional

Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS

NCT02415803
View directory record Official record
Conditions
Non ST Segment Elevation Acute Coronary Syndrome
Interventions
low-dose ticagrelor, conventional-dose ticagrelor, Clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

NCT02224703
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P, Placebo Control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

18790 - Sun Protection Factor Assay

NCT02695303
View directory record Official record
Conditions
Sunscreening Agent
Interventions
Coppertone (BAY 987516)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)

NCT04682405
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Uproleselan, Placebo, Melphalan
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A First in Human Study of RT001 in Patients With Friedreich's Ataxia

NCT02445794
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Low dose cohort, High dose cohort
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Long Beach, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 21, 2026, 1:09 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

NCT05409066
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Rituximab, Lenalidomide
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
31
States / cities
Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Sling vs Botox for Mixed Incontinence

NCT04171531
View directory record Official record
Conditions
Urinary Incontinence, Stress, Urinary Incontinence, Urge
Interventions
Botox® injection, Mid-urethral sling
Drug · Device
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 1Phase 2 Interventional

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

NCT01719302
View directory record Official record
Conditions
Stage III Adult Soft Tissue Sarcoma
Interventions
Gemcitabine, Docetaxel, Pazopanib
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07168902
View directory record Official record
Conditions
Glaucoma
Interventions
BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Glendale, California • Newport Beach, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

NCT00630253
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine, Hematopoietic Stem Cell Transplantation, Methylprednisolone, Filgrastim, Cyclosporine, Mycophenolate Mofetil
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 59 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 21, 2026, 1:09 AM EDT
Not yet recruiting Phase 1 Interventional

High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study

NCT07612345
View directory record Official record
Conditions
Pyruvate Kinase Deficiency, Glucose 6 Phosphate Dehydrogenase Deficiency
Interventions
Vitamin C
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

NCT00079937
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo, Fluticasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
56
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Early Phase 1 Interventional Results available

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

NCT03771157
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
Interventions
Shingrix vaccine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 1 Interventional

Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors

NCT02423057
View directory record Official record
Conditions
Neoplasms, Solid Tumors
Interventions
TdCyd
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Early-onset Alzheimer's Disease Study Protocol

NCT03507257
View directory record Official record
Conditions
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Flortaucipir, Florbetaben, Fluorodeoxyglucose
Drug
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 64 Years
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
18
States / cities
Sun City, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 3 Interventional

Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients

NCT00241501
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Esomeprazole (Nexium)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Wilmington, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 21, 2026, 1:09 AM EDT
Terminated Phase 1Phase 2 Interventional

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

NCT05427812
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2025 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2 Interventional

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

NCT02552277
View directory record Official record
Conditions
Diabetic Nephropathies, Peripheral Nervous System Diseases
Interventions
PDA-002, Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Garden Grove, California • Orange, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Early Phase 1 Interventional

Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia

NCT00993057
View directory record Official record
Conditions
Brain Neoplasms, Intracranial Aneurysm
Interventions
Insulin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

NCT00628628
View directory record Official record
Conditions
Tumor Lysis Syndrome
Interventions
As Needed Rasburicase, Fixed Dose Rasburicase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Feasibility Trial Testing the Bionic Pancreas With ZP4207

NCT02971228
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
Drug · Device
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 21, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

NCT05606965
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine, mRNA-1345, mRNA-1045
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 21, 2026, 1:09 AM EDT
Recruiting Phase 2 Interventional

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

NCT05340465
View directory record Official record
Conditions
Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions
Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
Drug
Lead sponsor
University of Washington
Other
Eligibility
Up to 3 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 21, 2026, 1:09 AM EDT